Theranostics, a major innovation in biotherapy monitoring
Currently, 70% of new medications are biotherapies and it seems crucial to determine precisely and objectively the patient response to a treatment.
Beyond simple diagnostics, theranostics is intended to give clinicians the means to implement a treatment customized for each patient while controlling the efficacy of the treatment by anticipating therapeutic escape and other secondary effects inherent in these biotherapies.
Theranostics tests thus constitute a new approach for monitoring these biotherapies, and a significant advance in the development of an individualized and responsible treatment.
Our approach is fully consistent with the current state of the health sector, in offering tests that allow a more judicious use of innovative but particularly expensive treatments.
Theradiag is the first diagnostics company to offer a complete solution for patients treated with anti-TNF alpha. Lisa-Tracker kits are the first CE marked reagents of an innovative line of products with high medical value.